These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 28741901)

  • 21. Long-term trends in hepatitis C prevalence, treatment uptake and liver-related events in the Swiss HIV Cohort Study.
    Baumann L; Braun DL; Cavassini M; Stoeckle M; Bernasconi E; Schmid P; Calmy A; Haerry D; Béguelin C; Fux CA; Wandeler G; Surial B; Rauch A
    Liver Int; 2024 Jan; 44(1):169-179. PubMed ID: 37850685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
    Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
    HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study.
    Soliman H; Ziada D; Salama M; Hamisa M; Badawi R; Hawash N; Selim A; Abd-Elsalam S
    Endocr Metab Immune Disord Drug Targets; 2020; 20(1):104-111. PubMed ID: 31448717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retrospective study of hepatitis C outcomes and treatment in HIV co-infected persons from the Australian HIV Observational Database.
    Puhr R; Wright ST; Hoy JF; Templeton DJ; Durier N; Matthews GV; Russell D; Law MG
    Sex Health; 2017 Aug; 14(4):345-354. PubMed ID: 28482168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.
    Uemura H; Tsukada K; Mizushima D; Aoki T; Watanabe K; Kinai E; Teruya K; Gatanaga H; Kikuchi Y; Sugiyama M; Mizokami M; Oka S
    PLoS One; 2017; 12(10):e0186255. PubMed ID: 29045448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.
    Calvaruso V; Ferraro D; Licata A; Bavetta MG; Petta S; Bronte F; Colomba G; Craxì A; Di Marco V
    J Viral Hepat; 2018 Jan; 25(1):72-79. PubMed ID: 28703895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis.
    Merchante N; Rivero-Juárez A; Téllez F; Merino D; Ríos-Villegas MJ; Villalobos M; Omar M; Rincón P; Rivero A; Pérez-Pérez M; Raffo M; López-Montesinos I; Palacios R; Gómez-Vidal MA; Macías J; Pineda JA;
    J Antimicrob Chemother; 2018 Sep; 73(9):2435-2443. PubMed ID: 29982683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals.
    Corma-Gómez A; Macías J; Téllez F; Freyre-Carrillo C; Morano L; Rivero-Juárez A; Ríos MJ; Alados JC; Vera-Méndez FJ; Merchante N; Palacios R; Granados R; Merino D; De Los Santos I; Pineda JA
    Clin Infect Dis; 2020 Dec; 71(9):2354-2362. PubMed ID: 31754695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort.
    Piroth L; Wittkop L; Lacombe K; Rosenthal E; Gilbert C; Miailhes P; Carrieri P; Chas J; Poizot-Martin I; Gervais A; Dominguez S; Neau D; Zucman D; Billaud E; Morlat P; Aumaitre H; Lascoux-Combe C; Simon A; Bouchaud O; Teicher E; Bani-Sadr F; Alric L; Vittecoq D; Boué F; Duvivier C; Valantin MA; Esterle L; Dabis F; Sogni P; Salmon D;
    J Hepatol; 2017 Jul; 67(1):23-31. PubMed ID: 28235612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.
    Neukam K; Morano-Amado LE; Rivero-Juárez A; Mancebo M; Granados R; Téllez F; Collado A; Ríos MJ; de Los Santos-Gil I; Reus-Bañuls S; Vera-Méndez F; Geijo-Martínez P; Montero-Alonso M; Suárez-Santamaría M; Pineda JA
    HIV Clin Trials; 2017 May; 18(3):126-134. PubMed ID: 28599618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of HCV eradication with direct-acting antiviral agents on serum gamma globulin levels in HCV and HCV/HIV coinfected patients.
    Milazzo L; van den Bogaart L; Sollima S; Oreni L; Lai A; Morena V; Bonazzetti C; Ridolfo Anna L; Antinori S
    Eur J Intern Med; 2020 May; 75():50-54. PubMed ID: 31980330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
    Steininger K; Boyd A; Dupke S; Krznaric I; Carganico A; Munteanu M; Neifer S; Schuetze M; Obermeier M; Arasteh K; Baumgarten A; Ingiliz P
    J Viral Hepat; 2017 Oct; 24(10):832-839. PubMed ID: 28439936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients.
    Arends JE; van der Meer JT; Posthouwer D; Kortmann W; Brinkman K; van Assen S; Smit C; van der Valk M; van der Ende M; Schinkel J; Reiss P; Richter C; Hoepelman AI; ;
    Neth J Med; 2015 Aug; 73(7):324-30. PubMed ID: 26314715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD4+ T-cell recovery in HIV/hepatitis C co-infected patients following successful hepatitis C treatment.
    Ryscavage P; Hussien S; Seung H; Hynicka L
    HIV Med; 2024 May; 25(5):622-627. PubMed ID: 38273652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
    Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. INSULIN RESISTANCE REDUCTION AFTER SUSTAINED VIROLOGICAL RESPONSE WITH DIRECT ACTING ANTIVIRAL:NOT EVERY POPULATION IMPROVES.
    Andrade VG; Yamashiro FDS; Oliveira CV; Moreira A; Winckler FC; Silva GF
    Arq Gastroenterol; 2018; 55(3):274-278. PubMed ID: 30540091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman.
    Hasson H; Messina E; Merli M; Della Torre L; Morsica G; Bagaglio S; Lazzarin A; Uberti-Foppa C
    Int J Infect Dis; 2014 Dec; 29():100-2. PubMed ID: 25449243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015.
    Spradling PR; Xing J; Rupp LB; Moorman AC; Gordon SC; Lu M; Teshale EH; Boscarino JA; Schmidt MA; Daida YG; Holmberg SD;
    J Clin Gastroenterol; 2018 Aug; 52(7):641-647. PubMed ID: 28590325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients.
    Beig J; Orr D; Harrison B; Gane E
    Liver Transpl; 2018 Aug; 24(8):1031-1039. PubMed ID: 29577581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting.
    Gayam V; Hossain MR; Khalid M; Chakaraborty S; Mukhtar O; Dahal S; Mandal AK; Gill A; Garlapati P; Ramakrishnaiah S; Mowyad K; Sherigar J; Mansour M; Mohanty S
    Gut Liver; 2018 Nov; 12(6):694-703. PubMed ID: 29938459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.